Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [8247]

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemotherapy

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to...

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple...

More than 260 new drugs to treat cancer? Researchers look for "new cures in old drugs"

More than 260 new drugs to treat cancer? Researchers look for "new cures in old drugs"

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared with current standard of care

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared...

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

Last Month in Oncology with Dr. Bishal Gyawali: November 2018

Last Month in Oncology with Dr. Bishal Gyawali: November 2018

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell...

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

More from ecancer